Gama-TocotrienolCAS# 14101-61-2 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 14101-61-2 | SDF | Download SDF |
PubChem ID | 5282349 | Appearance | Powder |
Formula | C28H42O2 | M.Wt | 410.6 |
Type of Compound | Phenols | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R)-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol | ||
SMILES | CC1=C(C=C2CCC(OC2=C1C)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)O | ||
Standard InChIKey | OTXNTMVVOOBZCV-WAZJVIJMSA-N | ||
Standard InChI | InChI=1S/C28H42O2/c1-20(2)11-8-12-21(3)13-9-14-22(4)15-10-17-28(7)18-16-25-19-26(29)23(5)24(6)27(25)30-28/h11,13,15,19,29H,8-10,12,14,16-18H2,1-7H3/b21-13+,22-15+/t28-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Gamma-Tocotrienol has antioxidant activity, it as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diets. 2. Gamma-Tocotrienol can induce the apoptosis on human gastric cancer SGC-7901 cells via mitochondria-dependent apoptosis pathway, it may as a potential, new chemopreventive agent for human gastric cancer. 3. Gamma-Tocotrienol is a novel blocker of the STAT3 activation pathway, with a potential role in future therapies for HCC and other cancers. |
Targets | Caspase | PARP | STAT | Src | JAK | Bcl-2/Bax | VEGFR | MEK | HIF | ERK |
Gama-Tocotrienol Dilution Calculator
Gama-Tocotrienol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4355 mL | 12.1773 mL | 24.3546 mL | 48.7092 mL | 60.8865 mL |
5 mM | 0.4871 mL | 2.4355 mL | 4.8709 mL | 9.7418 mL | 12.1773 mL |
10 mM | 0.2435 mL | 1.2177 mL | 2.4355 mL | 4.8709 mL | 6.0887 mL |
50 mM | 0.0487 mL | 0.2435 mL | 0.4871 mL | 0.9742 mL | 1.2177 mL |
100 mM | 0.0244 mL | 0.1218 mL | 0.2435 mL | 0.4871 mL | 0.6089 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Frangulin B
Catalog No.:BCC8175
CAS No.:14101-04-3
- 2-Thiouracil
Catalog No.:BCC4752
CAS No.:141-90-2
- Malonic acid
Catalog No.:BCN8534
CAS No.:141-82-2
- 2-Aminoethanol
Catalog No.:BCN1756
CAS No.:141-43-5
- Ricinoleic acid
Catalog No.:BCC8248
CAS No.:141-22-0
- Nerylacetate
Catalog No.:BCN3802
CAS No.:141-12-8
- Benzo-15-crown 5-ether
Catalog No.:BCC8849
CAS No.:14098-44-3
- Benzo-18-crown-6 ether
Catalog No.:BCC8850
CAS No.:14098-24-9
- (2R,3S)-Chlorpheg
Catalog No.:BCC6805
CAS No.:140924-23-8
- 6-Hydroxy-5,6-dehydrosugiol
Catalog No.:BCN3127
CAS No.:140923-35-9
- 4-Chloro-D-phenylalanine
Catalog No.:BCC2637
CAS No.:14091-08-8
- Aminopotentidine
Catalog No.:BCC6761
CAS No.:140873-26-3
- PACOCF3
Catalog No.:BCC7074
CAS No.:141022-99-3
- 1-Hydroxy-2,3,4,7-tetramethoxyxanthone
Catalog No.:BCN6506
CAS No.:14103-09-4
- Xanomeline oxalate
Catalog No.:BCC4146
CAS No.:141064-23-5
- JNK-IN-8
Catalog No.:BCC1673
CAS No.:1410880-22-6
- 12-Hydroxydodecanoic Acid
Catalog No.:BCN8405
CAS No.:505-95-3
- TRAP-6
Catalog No.:BCC3957
CAS No.:141136-83-6
- Epiguajadial B
Catalog No.:BCN4075
CAS No.:1411629-26-9
- 2-(Dimethylaminomethyl)-2-propanol
Catalog No.:BCN1774
CAS No.:14123-48-9
- Btk inhibitor 1
Catalog No.:BCC4238
CAS No.:1412418-47-3
- Asenapine hydrochloride
Catalog No.:BCC1371
CAS No.:1412458-61-7
- QS-21
Catalog No.:BCC8243
CAS No.:141256-04-4
- PEPA
Catalog No.:BCC5951
CAS No.:141286-78-4
gamma-Tocotrienol as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diets.[Pubmed:8121254]
Lipids. 1993 Dec;28(12):1113-8.
This study was designed to determine whether incorporation of gamma-tocotrienol or alpha-tocopherol in an atherogenic diet would reduce the concentration of plasma cholesterol, triglycerides and fatty acid peroxides, and attenuate platelet aggregability in rats. For six weeks, male Wistar rats (n = 90) were fed AIN76A semisynthetic test diets containing cholesterol (2% by weight), providing fat as partially hydrogenated soybean oil (20% by weight), menhaden oil (20%) or corn oil (2%). Feeding the ration with menhaden oil resulted in the highest concentrations of plasma cholesterol, low and very low density lipoprotein cholesterol, triglycerides, thiobarbituric acid reactive substances and fatty acid hydroperoxides. Consumption of the ration containing gamma-tocotrienol (50 mg/kg) and alpha-tocopherol (500 mg/kg) for six weeks led to decreased plasma lipid concentrations. Plasma cholesterol, low and very low density lipoprotein cholesterol, and triglycerides each decreased significantly (P < 0.001). Plasma thiobarbituric acid reactive substances decreased significantly (P < 0.01), as did the fatty acid hydroperoxides (P < 0.05), when the diet contained both chromanols. Supplementation with gamma-tocotrienol resulted in similar, though quantitatively smaller, decrements in these plasma values. Plasma alpha-tocopherol concentrations were lowest in rats fed menhaden oil without either chromanol. Though plasma alpha-tocopherol did not rise with gamma-tocotrienol supplementation at 50 mg/kg, gamma-tocotrienol at 100 mg/kg of ration spared plasma alpha-tocopherol, which rose from 0.60 +/- 0.2 to 1.34 +/- 0.4 mg/dL (P < 0.05). The highest concentration of alpha-tocopherol was measured in plasma of animals fed a ration supplemented with alpha-tocopherol at 500 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)
gamma-Tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells.[Pubmed:18602811]
J Nutr Biochem. 2009 Apr;20(4):276-84.
Tocotrienols are naturally occurring isoprenoid compounds highly enriched in palm oil, rice bran, oat, wheat germ, barley and rye. Tocotrienols have antioxidant properties as well as potent anticancer properties. In this study, the mechanisms underlying the apoptosis of gamma-tocotrienol on human gastric adenocarcinoma SGC-7901 cells were further studied, especially in correlation with the involvement of the apoptotic pathway. gamma-Tocotrienol inhibited SGC-7901 cell growth in a concentration- and time-dependent manner. The inhibitory effects of SGC-7901 cells were correlated with the DNA damage and arresting cell cycle at G(0)/G(1) phase in a time-dependent manner at 60 mumol/L concentration of gamma-tocotrienol. gamma-Tocotrienol induced activation of caspase-3 and increased the cleavage of the downstream substrate poly(ADP-ribose) polymerase. Furthermore, gamma-tocotrienol-induced apoptosis on SGC-7901 cells was mediated by activation of caspase-9. The data in this study suggested that gamma-tocotrienol could induce the apoptosis on human gastric cancer SGC-7901 cells via mitochondria-dependent apoptosis pathway. Thus, our findings revealed gamma-tocotrienol as a potential, new chemopreventive agent for human gastric cancer.
gamma-Tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line.[Pubmed:20452389]
Toxicology. 2010 Jul-Aug;274(1-3):27-33.
Hypoxia is a common characteristic feature of solid tumors, and carcinoma cells are known to secrete many growth factors. These growth factors, such as vascular endothelial growth factor (VEGF), play a major role in the regulation of tumor angiogenesis and metastasis. In this study, the effect of gamma-tocotrienol, a natural product commonly found in palm oil and rice bran, on the accumulation of HIF-1alpha protein and the paracrine secretion of VEGF in human gastric adenocarcinoma SGC-7901 cell line induced by cobalt(II) chloride (as a hypoxia mimic) was investigated. These results showed that cobalt(II) chloride induced the high expression of VEGF in SGC-7901 cells at dose of 150 micromol/L for 24h. Both basal level and cobalt(II) chloride-induced HIF-1alpha protein accumulation and VEGF paracrine secretion were inhibited in SGC-7901 cells treated with gamma-tocotrienol at 60 micromol/L treatment for 24 h. U0126, a MEK1/2 inhibitor, decreased the expression of HIF-1alpha protein and the paracrine secretion of VEGF under normoxic and hypoxic conditions. In this study, gamma-tocotrienol also significantly inhibited the hypoxia-stimulated expression of phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2). The mechanism seems to involve in inhibiting hypoxia-mediated activation of p-ERK1/2, it leads to a marked decrease in hypoxia-induced HIF-1alpha protein accumulation and VEGF secretion. These data suggest that HIF-1alpha/VEGF could be a promising target for gamma-tocotrienol in an effective method of chemoprevention and chemotherapy in human gastric cancer.
gamma-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent.[Pubmed:21198544]
Br J Pharmacol. 2011 May;163(2):283-98.
BACKGROUND AND PURPOSE: Activation of signal transducer and activator of transcription 3 (STAT3) play a critical role in the survival, proliferation, angiogenesis and chemoresistance of tumour cells. Thus, agents that suppress STAT3 phosphorylation have potential as cancer therapies. In the present study, we investigated whether the apoptotic, antiproliferative and chemosensitizing effects of gamma-tocotrienol are associated with its ability to suppress STAT3 activation in hepatocellular carcinoma (HCC). EXPERIMENTAL APPROACH: The effect of gamma-tocotrienol on STAT3 activation, associated protein kinases and phosphatase, STAT3-regulated gene products, cellular proliferation and apoptosis in HCC cells was investigated. KEY RESULTS: gamma-Tocotrienol inhibited both the constitutive and inducible activation of STAT3 with minimum effect on STAT5. gamma-Tocotrienol also inhibited the activation of Src, JAK1 and JAK2 implicated in STAT3 activation. Pervanadate reversed the gamma-tocotrienol-induced down-regulation of STAT3, suggesting the involvement of a protein tyrosine phosphatase. Indeed, we found that gamma-tocotrienol induced the expression of the tyrosine phosphatase SHP-1 and deletion of the SHP-1 gene by small interfering RNA abolished the ability of gamma-tocotrienol to inhibit STAT3 activation. gamma-Tocotrienol also down-regulated the expression of STAT3-regulated gene products, including cyclin D1, Bcl-2, Bcl-xL, survivin, Mcl-1 and vascular endothelial growth factor. Finally, gamma-tocotrienol inhibited proliferation, induced apoptosis and significantly potentiated the apoptotic effects of chemotherapeutic drugs (paclitaxel and doxorubicin) used for the treatment of HCC. CONCLUSIONS AND IMPLICATIONS: Overall, these results suggest that gamma-tocotrienol is a novel blocker of the STAT3 activation pathway, with a potential role in future therapies for HCC and other cancers.